J
Jupiter Endovascular
Health Tech & Medtech · Menlo Park, United States
Innovative endovascular devices enhancing cardiovascular health with cutting-edge technology MoreLess
Jupiter Endo is a medical technology company specializing in the development and commercialization of advanced endovascular devices aimed at improving cardiovascular health. The company serves healthcare providers, including hospitals and specialized cardiovascular clinics, operating in the global cardiovascular medical device market. Jupiter Endo's business model focuses on the research, development, and sale of innovative medical devices designed to treat various cardiovascular conditions. Revenue is generated through the direct sale of these devices to healthcare institutions and through strategic partnerships with other medical technology firms. The company leverages its extensive expertise in clinical affairs and product management to bring cutting-edge solutions to market, ensuring high standards of safety and efficacy.
Keywords: endovascular devices, cardiovascular health, medical technology, healthcare providers, innovation, clinical affairs, product management, global market, revenue generation, strategic partnerships.
Company overview
Jupiter Endovascular company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- —
- Headquarters
- Menlo Park, United States
- Employees
- 57
- Open positions
- 11
- Dealroom signal
- 0.0
Valuation & funding
Jupiter Endovascular funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Oct 2025 | $40M | $160M | Senvest Capital · Sonder Capital · LB Investment | ↗ |
| CORPORATE SPINOUT✓Other financing | Aug 2024 | $0 | — | Neptune Medical | ↗ |
| EARLY VC✓Equity / VC | Aug 2024 | $0 | — | Sonder Capital | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 57 |
| 2025 | 19 |
| 2024 | 19 |
Growth signals
Jupiter Endovascular website traffic
Latest recorded traffic for Jupiter Endovascular is 2.1K monthly website visits, up 90.9% over the last three months. Jupiter Endovascular's team grew 200% over the past year.
Hiring
Open positions at Jupiter Endovascular
Current openings linked to this company in Dealroom.
Comparisons
Jupiter Endovascular compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Jupiter Endovascular's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Jupiter Endovascular's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Jupiter Endovascular has talent and traffic
team presence
In the news
Latest news about Jupiter Endovascular
Recent press, funding announcements, and product moves mentioning Jupiter Endovascular — open to read from the original sources.
Market sentiment
What the market is saying about Jupiter Endovascular
An AI-synthesized read of the highest-engagement posts about Jupiter Endovascular on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Jupiter Endovascular’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.